Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial

June 4, 2020

Linzagolix

Jacques Donnez, M.D., Ph.D., Hugh S. Taylor, M.D., Ph.D., Robert N. Taylor, M.D., Ph.D., Mark D. Akin, M.D., Tatyana F. Tatarchuk, M.D., Dr. Sc., Krzysztof Wilk, M.D., Jean-Pierre Gotteland, Ph.D., Veronique Lecomte, Pharm.D., Elke Bestel, M.D.

Published online: June 03, 2020

Donnez, Jacques et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial. Fertility and Sterility, Volume 114, Issue 1, July 2020, Pages 44-55

Read more

Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis

June 3, 2020

Linzagolix

Olivier Donnez M.D., Ph.D. , Jacques Donnez M.D., Ph.D.

Published online: June 02, 2020

Donnez, Olivier et al. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis. Fertility and Sterility, Volume 114, Issue 3, September 2020, Pages 640-645

Read more

Linzagolix for Endometriosis-Associated Pain: Lipid Changes After 52 Weeks of Treatment

April 24, 2020

Linzagolix

Bestel, Elke MD; Gotteland, Jean-Pierre PhD; Donnez, Jacques MD, PhD; Taylor, Robert N. MD, PhD; Garner, Elizabeth I. MD, MPH

ACOG Annual Conference, April 2020

Obstetrics & Gynecology: May 2020 – Volume 135 – Issue – p 25S doi: 10.1097/01.AOG.0000663180.46470.c9

Read more

Quality of Life Results After 52 Weeks of Treatment With Linzagolix for Endometriosis-Associated Pain

Linzagolix

Bestel, Elke MD; Gotteland, Jean-Pierre PhD; Donnez, Jacques MD, PhD; Taylor, Robert N. MD, PhD; Garner, Elizabeth I. MD, MPH

ACOG Annual Conference, April 2020

Obstetrics & Gynecology: May 2020 – Volume 135 – Issue – p 26S-27S doi: 10.1097/01.AOG.0000663200.75027.38

Read more

Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern

February 26, 2020

Linzagolix

Pohl O., Marchand L., Bell D., Gotteland JP.

Pohl O, Marchand L, Bell D, Gotteland JP. Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern. Reprod Sci. 2020;27(4):988‐995. doi:10.1007/s43032-020-00172-z

Read more

Babies Born Following Administration of Nolasiban Before Embryo Transfer (ET) After IVF: Neonatal and Infant Development Outcomes From a Double-Blind, Placebo-Controlled, Clinical Trial

October 7, 2019

Nolasiban

Humberstone A., Terrill P., Macgregor L., Loumaye E.

ASRM 2019 Scientific Congress & Expo, 12-16 October 2019, Philadelphia, PA

Fertility and Sterility Vol. 112, No. 3, Supplement, September 2019. Abstract on pages e7-e8.

Read more

Long Term Treatment of Endometriosis Associated Pain (EAP) With Linzagolix: Efficacy and Safety After 12 Months of Treatment

Linzagolix

Taylor R., Bestel E., Gotteland JP., Lecomte V., Dubouloz R., Terrill P., Humberstone A., Loumaye E.

ASRM 2019 Scientific Congress & Expo, 12-16 October 2019, Philadelphia, PA

Fertility and Sterility Vol. 112, No. 3, Supplement, September 2019. Abstract on page e323.

Read more

The Effect of Linzagolix on Bone Mineral Density (BMD): Safety Results From a Dose-Ranging Trial

May 20, 2019

Linzagolix

Elke Bestel, Andrew Humberstone, Veronique Lecomte, Ernest Loumaye, Jean-Pierre Gotteland, James A. Simon

ACOG Annual Conference, 03-06 May 2019, Nashville, TN

Obstetrics & Gynecology: May 2019 – Volume 133 – Issue – p 112S-113S doi:10.1097/01.AOG.0000558837.48634.b6

Read more

Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F2α-induced Contractions and Inflammatory Responses in Human Myometrium

April 8, 2019

Nolasiban

Sung Hye Kim, Lucia Riaposova, Hauwa Ahmed, Oliver Pohl, André Chollet, Jean-Pierre Gotteland, Aylin Hanyaloglu, Phillip R. Bennett & Vasso Terzidou

Kim SH, Riaposova L, Ahmed H, et al. Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F2α-induced Contractions and Inflammatory Responses in Human Myometrium. Sci Rep. 2019;9(1):5792. Published 2019 Apr 8. doi:10.1038/s41598-019-42181-2

Read more

Co‐administration of the prostaglandin F2α receptor antagonist pre‐term labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone

March 25, 2019

OBE022

Oliver Pohl, Line Marchand, Jean‐Pierre Gotteland, Simon Coates, Jörg Täubel, Ulrike Lorch

Pohl, O, Marchand, L, Gotteland, J‐P, Coates, S, Täubel, J, Lorch, U. Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone. Br J Clin Pharmacol. 2019; 85: 1516– 1527.https://doi.org/10.1111/bcp.13925

Read more